CureVac Shareholders Face a Critical Deadline

CureVac NL0015436031

For remaining investors in CureVac, the clock is ticking down to a decisive moment. The company’s journey as an independent entity is concluding, following BioNTech’s successful acquisition of a controlling stake. Shareholders who have not yet accepted the exchange offer must now act swiftly, as the expiration of the current acceptance window could lead to significant disadvantages, including the potential delisting of the stock.